Observational Study Comparing Efficacy and Safety between Neoadjuvant Concurrent Chemoradiotherapy and Chemotherapy for Patients with Unresectable Locally Advanced or Metastatic Gastric Cancer

Table 2

Grade 3/4 toxicities according to the National Cancer Institute Common Terminology Criteria for Adverse Events.

	Total N = 65 (%)	CCRT N = 30 (%)	Chemotherapy N = 35 (%)	value
Hematologic	8 (12.3)	3 (10.0)	5 (14.3)	1.000
Neutropenia	4 (6.2)	2 (6.7)	2 (5.7)	1.000
Febrile neutropenia	3 (4.6)	1 (3.3)	2 (5.7)	1.000
Thrombocytopenia	1 (1.5)	0	1 (2.9)	1.000
Nonhematologic	44 (67.7)	20 (66.7)	24 (68.6)	0.768
Nausea/vomiting	10 (15.4)	5 (16.7)	5 (14.3)	1.000
Anorexia/fatigue	9 (13.8)	4 (13.3)	5 (14.3)	0.708
Abnormal liver function	5 (7.7)	2 (6.7)	3 (8.6)	1.000
Abnormal renal function	5 (7.7)	2 (6.7)	3 (8.6)	1.000
Peripheral neuropathy	4 (6.2)	2 (6.7)	2 (5.7)	1.000
Stomatitis	4 (6.2)	3 (10.0)	1 (2.9)	0.270
Diarrhea	4 (6.2)	2 (6.7)	2 (5.7)	1.000
Constipation	3 (4.6)	0	3 (8.6)	0.255

CCRT = concurrent chemoradiotherapy.